Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

44.27 +0.33 (+0.74%)
Streaming Delayed Price Updated: 3:47 PM EDT, May 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
55 56 Next >
Johnson & Johnson, Other Pharma Makers Anticipate Reformulated Injectable Drugs May Exclude Price Negotiations
Cancer drug manufacturers, including Johnson & Johnson (NYSE: JNJ), anticipate that injectable versions of some popular treatments will not be included in U.S. 
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Roku To Rally Around 25%? Here Are 10 Other Analyst Forecasts For Friday
JP Morgan boosted the price target for Intel Corporation (NASDAQ: INTC) from $30 to $35. JP Morgan analyst Harlan Sur maintained an Underweight rating. Intel shares rose 6.8% to $36.91 in pre-market... 
Via Benzinga
Bristol Myers Squibb (BMY) Q2 2023 Earnings Call Transcript
BMY earnings call for the period ending June 30, 2023. 
Via The Motley Fool
Bristol Myers Squibb Misses Q2 Earnings And Revenue Estimates
Bristol Myers Squibb came out with quarterly earnings of $1.75 per share. 
Via Talk Markets
2 Dirt Cheap Dividend Stocks to Buy Right Now
Business never sleeps for these companies. 
Via The Motley Fool
Preview: Bristol-Myers Squibb's Earnings
Via Benzinga
Bristol-Myers Squibb Unusual Options Activity
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
  Friday's session saw 59 companies set new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
  During Thursday, 56 stocks hit new 52-week lows. 
Via Benzinga
2 Cheap High-Yield Dividend Stocks to Buy Now
These two pharma stocks are top-notch passive income vehicles. 
Via The Motley Fool
Bristol Myers Squibb's Stocks Falls on Q2 Miss, FY23 Forecast Cut As Two Of Its Top Drugs Face Generic Competition
Bristol Myers Squibb & Co (NYSE: BMY) said that its Q2 revenues of $11.23 billion declined 6% Y/Y, or 5% when adjusted for foreign exchange, due to lower sales of Revlimid, partially offset by in-line... 
Via Benzinga
US Stocks Buckle Up For Solid Open On Meta's Earnings Boost, Fed Relief — But Analyst Advises Some 'Value-Style' Rebalancing
Stocks could be heading to a higher open on Thursday, as traders digest some positive earnings reports and look ahead to another batch of economic data. 
Via Benzinga
Exscientia is the Sniper of the AI Drug Discovery Industry
News of a $50 million investment by artificial intelligence (AI) leader Nvidia Co. (Nasdaq: NVDA) into AI-powered drug discovery company Recursion 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Why Immatics Shares Are Rising Today
Immatics N.V. (NASDAQ: IMTX) shares are trading higher after the company announced  
Via Benzinga
Analyst Expectations for Bristol-Myers Squibb's Future
Via Benzinga
What Does Bristol-Myers Squibb's Debt Look Like?
Via Benzinga
Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
From Bristol Myers Squibb
Via Business Wire
Investor Sentiment Declines After Fed Raises Interest Rates By 0.25%
The CNN Money Fear and Greed index showed further decline in overall sentiment among U.S. investors on Wednesday. The Dow Jones closed higher on Wednesday, recording its longest winning streak since... 
Via Benzinga
McDonald's, Meta Platforms And 3 Stocks To Watch Heading Into Thursday
With U.S. stock futures trading higher this morning on Thursday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
Big Weeks Ahead For MedTech And Life Science Stocks
It’s a big week for earnings that may change the trajectory of the rally but more than likely will continue the rotation into different sectors. 
Via Talk Markets
The 3 Most Undervalued Pharma Stocks to Buy Now: July 2023
Trading below a 15 forward price-to-earnings, these undervalued pharma stocks offer opportunities in an overbought market. 
Via InvestorPlace
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma
From Bristol Myers Squibb
Via Business Wire
Bristol-Myers Squibb Company (NYSE: BMY) Making Surprising Moves in Thursday Session
Via Investor Brand Network
Exposures COVID-19
Drug Pricing Negotiation Program: Johnson & Johnson Joins Legal Battle Against US Government
Johnson & Johnson (NYSE: JNJ) has reportedly taken legal action against the U.S. 
Via Benzinga
The Acute Hospital Care Market Is Worth Over $3 Trillion, And Windtree Therapeutics Brings A First-In-Class Drug To An Active Segment Of This Market
The global acute hospital care market was worth $3.2 trillion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 5.62% from 2023 to 2030. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 14, 2023
Via Benzinga
Gilead Boosts Biotech Footprint With Stakes In AlloVir And Arcus
Regulatory filings show Gilead Sciences' purchase of shares in AlloVir and Arcus. Strategic investments in the biotech sector are fairly common to boost growth. 
Via MarketBeat
Topics Retirement
Exposures Pension
Medical Management Of Deadly Urgent Cardiogenic Shock Largely Remains A Challenge – Windtree Therapeutics (NASDAQ: WINT) Is Helping Change That
Windtree Therapeutics, Inc. (NASDAQ: WINT), a biotechnology company treating late-stage acute cardiovascular disorders, is advancing its first-in-class drug for serious heart conditions. 
Via Benzinga
Bristol Myers Squibb Launches Supporting You with UC, with Women’s World Cup Commentator, Former Professional Soccer Player and Ulcerative Colitis Patient, Rosie White
From Bristol Myers Squibb
Via Business Wire
< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
55 56 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.